The stock of Immunovant Inc (IMVT) has gone up by 2.55% for the week, with a -8.50% drop in the past month and a 74.78% rise in the past quarter. The volatility ratio for the week is 4.95%, and the volatility levels for the past 30 days are 4.52% for IMVT. The simple moving average for the last 20 days is 0.96% for IMVT stock, with a simple moving average of 54.81% for the last 200 days.

Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?

, and the 36-month beta value for IMVT is at 0.70. Analysts have varying views on the stock, with 13 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price suggested by analysts for IMVT is $47.71, which is $12.19 above the current market price. The public float for IMVT is 51.94M, and currently, shorts hold a 12.87% of that float. The average trading volume for IMVT on November 16, 2023 was 2.20M shares.

IMVT) stock’s latest price update

Immunovant Inc (NASDAQ: IMVT) has seen a decline in its stock price by -2.09 in relation to its previous close of 34.97. However, the company has experienced a 2.55% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-14 that Immunovant continues to show promising developments in anti-FcRn platform’s clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, could significantly impact the company’s valuation and future trajectory. Immunovant’s financial stability and strategic market positioning support a buy rating, with the potential for significant market penetration and revenue generation.

Analysts’ Opinion of IMVT

Many brokerage firms have already submitted their reports for IMVT stocks, with UBS repeating the rating for IMVT by listing it as a “Buy.” The predicted price for IMVT in the upcoming period, according to UBS is $55 based on the research report published on October 13, 2023 of the current year 2023.

IMVT Trading at 8.64% from the 50-Day Moving Average

After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.52% of loss for the given period.

Volatility was left at 4.52%, however, over the last 30 days, the volatility rate increased by 4.95%, as shares sank -7.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.74% upper at present.

During the last 5 trading sessions, IMVT rose by +2.55%, which changed the moving average for the period of 200-days by +92.68% in comparison to the 20-day moving average, which settled at $33.78. In addition, Immunovant Inc saw 92.90% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IMVT starting from Levine Mark S., who sale 4,107 shares at the price of $34.66 back on Oct 25. After this action, Levine Mark S. now owns 310,381 shares of Immunovant Inc, valued at $142,349 using the latest closing price.

Macias William L., the Chief Medical Officer of Immunovant Inc, sale 530 shares at $36.80 during a trade that took place back on Oct 19, which means that Macias William L. is holding 336,862 shares at $19,504 based on the most recent closing price.

Stock Fundamentals for IMVT

The total capital return value is set at -49.80, while invested capital returns managed to touch -50.62. Equity return is now at value -78.84, with -70.88 for asset returns.

Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.43 points at debt to equity in total, while total debt to capital is 0.43. Total debt to assets is 0.39, with long-term debt to equity ratio resting at 0.01. Finally, the long-term debt to capital ratio is 0.01.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.34.


In conclusion, Immunovant Inc (IMVT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.